𝔖 Bobbio Scriptorium
✦   LIBER   ✦

WSD 09 (2) - Immunotherapy of Tumors: Clinical Aspects


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
113 KB
Volume
39
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Renal medullary carcinoma: Clinical and
✍ Robert A. Avery; Jules E. Harris; Charles J. Davis Jr.; Digamber S. Borgaonkar; πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 537 KB

The opinions expressed herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

Clinical aspects of the rhabdoid tumor o
✍ Palmer, Nigel F. ;Sutow, Wataru πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 374 KB

Rhabdoid tumor of the kidney (RTK), originally described as a monophasic sarcomatous variant of Wilms' tumor, is now recognized as a highly malignant, non-Wilms' tumor possibly of neuroectodermal origin. Twenty-one National Wilms' Tumor Study patients with this tumor were treated in the years 1969 t

Disialoganglioside GD2 and a novel tumor
✍ Modak, Shakeel ;Gerald, William ;Cheung, Nai-Kong V. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 192 KB

## Abstract ## Background Desmoplastic small round cell tumor (DSRCT) is an aggressive and often misdiagnosed neoplasm of children and young adults. It is chemotherapy‐sensitive, yet patients often relapse off therapy because of residual microscopic disease at distant sites: peritoneum, liver, lym

Serum-mediated blocking of cell-mediated
✍ Nelson L. Levy; M. S. Mahaley Jr.; Eugene D. Day πŸ“‚ Article πŸ“… 1972 πŸ› John Wiley and Sons 🌐 French βš– 318 KB πŸ‘ 1 views

## Abstract A patient with melanoma was found to have lymphocytes highly cytotoxic for autogenous tumor cells but not for fibroblasts. Autogenous serum did not block the cytotoxicity. He then received an injection of BCG into a small tumor nodule. Three weeks later, in association with accelerated

Specific active immunotherapy in patient
✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received